Deals

J&J, Merck and Boston Scientific Go on $6.4 Billion Buying Spree

The Johnson & Johnson headquarters in New Brunswick, New Jersey. — The Johnson & Johnson headquarters in New Brunswick, New Jersey.
Photographer: Mark Kauzlarich/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Take our Survey

By Fiona Rutherford

January 8, 2024 at 5:02 PM UTC

Updated on

January 8, 2024 at 6:13 PM UTC

This article is for subscribers only.

More than $6.4 billion in health-care deals were announced on Monday as the annual JPMorgan Healthcare Conference kicked off in San Francisco.

The deals include Merck & Co.’s $680 million purchase of cancer drugmaker Harpoon Therapeutics Inc., Boston Scientific Corp.’s $3.7 billion acquisition of device-maker Axonics Inc. and Johnson & Johnson’s $2 billion deal to buy Ambrx Biopharma Inc., whose therapies target tumors with lethal drugs.